Author:
M. Meil William,Farrell William,Satti Reem
Abstract
Substance Use Disorders are a substantial public health concern whose treatment remains challenging. High rates of relapse are in fact a hallmark of drug addiction despite the wide variety of psychotherapeutic and pharmacotherapeutic approaches. This chapter discusses three innovative and controversial therapeutic approaches for Substance Use Disorders that have received considerable attention: the use of classic serotonergic hallucinogenic drugs (LSD and psilocybin), addiction immunotherapy and anti-addiction vaccines, and the use of transcranial magnetic stimulation. These treatments are not necessarily new but are discussed because they represent a diverse set of approaches that address varied aspects of drug addiction. Furthermore, they have an accumulated body of research from which to assess their future viability. For each of these therapeutic approaches this chapter considers the theoretical basis for use, history, status of the literature supporting their use, limitations, and potential applications. While these three interventions represent highly varied approaches to the treatment of Substance Use Disorders, this diversity may be necessary given the complex nature of addictive disorders.
Reference100 articles.
1. Arria AM, McLellan TA. Evolution of concept - But not action - in addiction treatment. Substance Use Misuse. 2012; 47:1041-1048. DOI: 10.3109/10826084.2012.663273
2. Fleury M-JJ, Djouini A, Huỳnh C, Tremblay J, Ferland F, Menard JM, et al. Remission from substance use disorders: A systematic review and meta-analysis. Drug and Alcohol Dependence. 2016;168:293-306. DOI.org/10.1016/j.drugalcdep.2016.08.625
3. Bahorik AL, Satre DD, Kline-Simon AH, Weisner CM, Campbell CI. Alcohol, cannabis, and opioid use disorders, and disease burden in an integrated healthcare system. Journal of Addiction Medicine. 2017; 1(1):3-9. DOI: 10.1097/ADM.0000000000000260
4. Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/
5. McLellan TA, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness implication for treatment, insurance, and outcomes Evaluation. JAMA. 2000;284(13):1689-1695. DOI: 10.1001/jama.284.13.1689